Scarica l'app Stockscreener
20.30
6.19%
-1.34
Precedente Chiudi:
$21.64
Aprire:
$21.6
Volume 24 ore:
1.18M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.79B
Reddito:
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-9.8568
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
-13.14%
1M Prestazione:
-26.29%
6M Prestazione:
-33.57%
1 anno Prestazione:
-52.76%
Intervallo 1D:
$20.12
$21.60
Intervallo di 1 settimana:
$20.12
$23.10
Portata 52W:
$20.12
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
20.30 | 1.79B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | UBS | Neutral |
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
An officer's proposed share sale at Mineralys Therapeutics (MLYS) lists a $78.1K market value. - Stock Titan
Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 - GlobeNewswire Inc.
After a CEO share sale, 528,621 shares remain with Mineralys Therapeutics (MLYS) chief. - Stock Titan
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 - GlobeNewswire Inc.
A 75,000-share sale is proposed by a Mineralys (MLYS) officer and director. - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares - Investing.com
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million. - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Mineralys Therapeutics Inc For: 22 September - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics (MLYS) officer lines up new stock option sale - stocktitan.net
A new employee gets Mineralys stock awards covering 14,880 and 11,160 shares - Stock Titan
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan - Stock Titan
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics director Karydas sells $85,740 in stock - Investing.com
Mineralys Therapeutics (MLYS) director sells shares under preset plan - stocktitan.net
Mineralys Therapeutics (NASDAQ: MLYS) executive plans new stock option sale after recent $388K trade - stocktitan.net
Mineralys (NASDAQ: MLYS) officer to sell 3,000 shares via options - stocktitan.net
Mineralys (MLYS) officer to sell 7,709 shares - stocktitan.net
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mineralys Therapeutics grants inducement equity awards covering 52,080 shares to new hires - Bitget
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com - Investing.com Canada
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) insider to sell 2,171 shares via cashless option exercise - Stock Titan
Two new hires get four-year stock awards from Mineralys - stocktitan.net
Mineralys Therapeutics Market Sentiment - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com UK
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - stocktitan.net
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares - Investing.com
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - stocktitan.net
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mineralys Therapeutics Inc Azioni (MLYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer |
Sep 30 '26 |
Sale |
25.46 |
75,000 |
1,909,665 |
528,621 |
| Congleton Jon | Officer |
Sep 30 '26 |
Proposed Sale |
25.46 |
75,000 |
1,909,662 |
0 |
| Slingsby Brian Taylor | Director |
Sep 22 '26 |
Sale |
28.81 |
104,320 |
3,005,303 |
7,805,718 |
| CATALYS PACIFIC FUND LP | Director |
Sep 22 '26 |
Proposed Sale |
28.81 |
104,320 |
3,005,303 |
0 |
| Warren Eric | Officer |
Sep 21 '26 |
Proposed Sale |
28.12 |
7,438 |
209,135 |
0 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Option Exercise |
13.24 |
7,438 |
98,479 |
45,838 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Sale |
28.12 |
7,438 |
209,136 |
38,400 |
| Rodman David Malcom | Officer |
Sep 17 '26 |
Proposed Sale |
27.95 |
417 |
11,655 |
0 |
| Karydas Daphne | Officer |
Sep 15 '26 |
Proposed Sale |
28.58 |
3,000 |
85,740 |
0 |
| Karydas Daphne | Director |
Sep 15 '26 |
Option Exercise |
12.02 |
3,000 |
36,060 |
9,200 |
3.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):